Telix Pharmaceuticals specializes in cancer radiopharmaceuticals.

Telix Pharmaceuticals Ltd. (Ticker: TLX US) is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. Specializing in theranostic radiopharmaceuticals for cancer treatment and diagnostics, Telix Pharmaceuticals plans to raise $202 million in a Nasdaq IPO on June 14, 2024. The company will issue 17 million American Depositary Shares (ADS) at $11.87 per share.

Telix generated $380.4 million in revenue and $25.9 million in net income over the last 12 months. The company has a market cap of $4.2 billion and trades under the symbol TLX on the ASX. The IPO proceeds will support the development and commercialization of Telix's extensive product pipeline, which includes innovative imaging agents and therapeutic radiopharmaceuticals targeting various cancers such as prostate, kidney, and brain.

Jefferies, Morgan Stanley, Truist Securities, and William Blair are the underwriters for the IPO. Telix Pharmaceuticals was founded in 2017, and its headquarters are located in Melbourne, Australia.